AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17052775
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 2.5 mg/day (group A)
Trial: 17052775
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 2.5 mg/day (group A) in patients with MTHFR 677TT mutation
Trial: 11601949
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of medications and health conditions, details not available
Trial: 30096354
Drug: Intravitreous ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreous ranibizumab (0.5 mg)
Trial: 19435154
Drug: Motor coordination
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motor coordination training for 20 minutes daily over 3 weeks
Trial: 360495
Drug: Intravenous infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusions of 10% glycerol in 0.9% NaCl‐‐5% glucose solutions administered twice daily for 6 days to 26 patients
Trial: 30916203
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of hypertension
Trial: 25413168
Drug: Cognitive‐behavioural training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioural training programme for pain management (6 weekly group sessions supervised by a psychologist and a physiotherapist)
Trial: 23331443
Drug: ramipril 2.5
RxNorm normalized name: ramipril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril 2.5 mg daily
Trial: 19671411
Drug: Oxymatrine Capsule,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymatrine Capsule, 0.4 g once a day for 3 months
Trial: 15631714
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of Triptorelin (3.75 mg) at 6 weeks intervals in group A
Trial: 15631714
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of Triptorelin (3.75 mg) at 4 weeks intervals in group B
Trial: 17219967
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment regimes (SC and IM)
Trial: 11705848
Drug: 4-hydroxyphenylretinamide (4-HPR)
RxNorm normalized name: 4-HPR
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-hydroxyphenylretinamide (4-HPR) at 200 mg/day for 6 months (with a 3-day/month drug holiday)
Trial: 22420538
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment (SMT) including NIV if indicated
Trial: 8365971
Drug: BCAA (leucine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA (leucine + isoleucine + valine, 77 mg/kg)
Trial: 8365971
Drug: Placebo (dextrose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (dextrose, 77 mg/kg)
Trial: 25818103
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention (diet, smoking cessation, and exercise) with oral and written information provided in a booklet for postoperative rehabilitation.
Trial: 23864581
Drug: Metformin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin monotherapy (more than 360 defined daily doses)
Trial: 23864581
Drug: Antidiabetic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidiabetic drugs other than metformin
Trial: 10365640
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg/d for 1 week
Trial: 9816035
Drug: Amonafide at
RxNorm normalized name: amonafide
DrugBank: Amonafide (DB05022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amonafide at 300 mg/m2/day i.v. for 5 days, repeated at 21-day intervals for a maximum of four cycles.
Trial: 7003611
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg DT gamma E (intra-muscular injections for 4 days)
Trial: 28242714
Drug: Time-averaged on-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-averaged on-treatment SBP at 120 to 130 mm Hg (mean, 126.2 mm Hg)
Trial: 28242714
Drug: Time-averaged on-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-averaged on-treatment SBP at 130 to 135 mm Hg (mean, 132.6 mm Hg)
Trial: 28242714
Drug: Time-averaged on-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-averaged on-treatment SBP at 135 to 140 mm Hg (mean, 137.5 mm Hg)
Trial: 28242714
Drug: Time-averaged on-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-averaged on-treatment SBP <120 mm Hg (mean, 116.7 mm Hg)
Trial: 8341998
Drug: Six-month therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six-month therapy with daily Rifater for two months, followed by isoniazid and rifampicin for four months (n = 128)
Trial: 8341998
Drug: Initial drug
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial drug resistance to isoniazid
Trial: 8341998
Drug: Subsequent multi-drug
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent multi-drug therapy
Trial: 31113475
Drug: Antibiotics at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics at home
Trial: 25839406
Drug: ombitasvir/paritaprevir/ritonavir (25mg/150mg/100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ombitasvir/paritaprevir/ritonavir (25mg/150mg/100mg once daily) and dasabuvir (250mg twice daily) + weight-based ribavirin for 12 weeks
Trial: 24067081
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline (23 ml/kg)
Trial: 24067081
Drug: 5% glucose
RxNorm normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glucose (23 ml/kg)
Trial: 17182222
Drug: Monthly booster
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly booster sessions for a further nine months
Trial: 12235221
Drug: Two-drug combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-drug combinations containing at least one new agent
Trial: 16163169
Drug: Newer targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer targeted therapies
Trial: 9555615
Drug: Cetirizine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine treatment for one week
Trial: 7480963
Drug: r-alpha-IFN-2a (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-alpha-IFN-2a (3 MU thrice weekly for 12 months)
Trial: 7480963
Drug: r-alpha-IFN-2b (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-alpha-IFN-2b (3 MU thrice weekly for 12 months)
Trial: 31735634
Drug: Ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.5 mg and 2.0 mg) administered monthly or on an as-needed basis (PRN)
Trial: 29265836
Drug: Compassion-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compassion-focused therapy (CFT) as guided self-help
Trial: 1276560
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (placebo treatment)
Trial: 23885649
Drug: Delayed surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed surgery (>5 days) for patients on antiplatelet therapy
Trial: 23885649
Drug: Early surgery
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early surgery (<48 h) for patients not on antiplatelet therapy
Trial: 11700577
Drug: Tafenoquine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 400 mg for 3 days followed by placebo weekly
Trial: 7944932
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interferon gamma, 100 micrograms, administered subcutaneously once daily for 21 days (or until patient discharge if prior to 21 days)
Trial: 23420574
Drug: 400 ml
RxNorm normalized name: Lantidra 400 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 ml beer (4.7% vol)
Trial: 23420574
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml red wine (13.7% vol)
Trial: 23420574
Drug: Whisky and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whisky and high proof ethanol solution
Trial: 12731402
Drug: Magnetostimulation (Viofor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetostimulation (Viofor JPS system; M2P2 program; induction‐‐25‐80 microT; frequency‐‐200 Hz, complex saw‐like shape) applied for 12 min daily, repeated 15 times
Trial: 10431577
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy followed by hematopoietic stem cell transplant
Trial: 7742127
Drug: Contrast-enhanced MR
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced MR imaging using high dose (0.3 mmol/kg b.w.) Gadodiamide injection
Trial: 7742127
Drug: Contrast-enhanced MR
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced MR imaging using standard dose (0.1 mmol/kg b.w.) Gadodiamide injection
Trial: 1952841
Drug: Rimantadine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimantadine (10 days treatment)
Trial: 1952841
Drug: Rimantadine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimantadine (5 days treatment)
Trial: 6452790
Drug: Zimelidine (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine (selective serotonin‐uptake inhibitor)
Trial: 10674508
Drug: rapacuronium 2
RxNorm normalized name: rapacuronium 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rapacuronium 2 mg x kg(‐1)
Trial: 8554083
Drug: Higher, conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher, conventional dose of levodopa and carbidopa
Trial: 6285445
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg, 3 times daily)
Trial: 2113764
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg, 3 times daily)
Trial: 30845731
Drug: Combined supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined supplementation with glycine (3.0 g) and tryptophan (0.2 g)
Trial: 27266506
Drug: Auricular point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular point acupressure (APP) treatment using vaccaria seeds on the large intestine point (CO7)
Trial: 21883559
Drug: Biomechanical preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomechanical preparation
Trial: 18004131
Drug: Ethanol (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.7 g/kg)
Trial: 9802364
Drug: Fel d
RxNorm normalized name: Anti-cat allergen fel d 1 monoclonal anitbody regn-1908
DrugBank: Freneslerbart (DB19080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fel d 1 peptides (high dose, 750 micro(g))
Trial: 9802364
Drug: Fel d
RxNorm normalized name: Anti-cat allergen fel d 1 monoclonal anitbody regn-1908
DrugBank: Freneslerbart (DB19080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fel d 1 peptides (medium dose, 75 micro(g))
Trial: 9802364
Drug: Fel d
RxNorm normalized name: Anti-cat allergen fel d 1 monoclonal anitbody regn-1908
DrugBank: Freneslerbart (DB19080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fel d 1 peptides (low dose, 7.5 micro(g))
Trial: 26491117
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (9 mg elemental zinc daily for 4 weeks)
Trial: 26491117
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical tablet for 4 weeks)
Trial: 24036613
Drug: Intraoperative periarticular
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative periarticular infiltration with ropivacaine, clonidine, morphine, epinephrine and corticosteroids
Trial: 8424508
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (PCA) with morphine
Trial: 24036613
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion with ropivacaine
Trial: 15312558
Drug: Oseltamivir (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (75 mg, twice daily for 5 days)
Trial: 11224816
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BSA and resistance exercise (SAR)
Trial: 22344198
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot (both doses)
Trial: 20631016
Drug: Decrease in
RxNorm normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease in insulin sensitivity (1 mg x kg(‐1) x min(‐1))
Trial: 2180105
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 40 mg per day for two weeks
Trial: 6110436
Drug: Isoprenaline 10
RxNorm normalized name: Isoprénaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoprenaline 10 or 20 mg sublingually 30 min before the meal
Trial: 6110436
Drug: Salbutamol 4
RxNorm normalized name: Salbutamol 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 4 mg four times daily for 1 week
Trial: 6110436
Drug: Propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 40 mg four times daily for 1 week (after isoprenaline)
Trial: 29541927
Drug: Treatment preference
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment preference (preferred vs non-preferred)
Trial: 29541927
Drug: Pharmacotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy with sertraline (SER)
Trial: 26514581
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral THC
Trial: 10211146
Drug: Olanzapine (5‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5‐20 mg)
Trial: 10211146
Drug: Haloperidol (5‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (5‐20 mg)
Trial: 2196085
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CyA) at 2.5 mg/kg/day
Trial: 2196085
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CyA) at 5 mg/kg/day
Trial: 19337010
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart 30 (BIAsp30) + metformin (met)
Trial: 19337010
Drug: Premixed human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premixed human insulin 30/70 (BHI30) + metformin (met)
Trial: 11440285
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg/d
Trial: 17261662
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg/d (in patients without a history of HF)
Trial: 15289727
Drug: Low-dose daily
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose daily chemotherapy (50 mg carboplatin and 50 mg etoposide)
Trial: 15289727
Drug: High-dose hyperfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose hyperfractionated radiation therapy (69.6 Gy) with concurrent chemotherapy
Trial: 15289727
Drug: Weekend chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekend chemotherapy group
Trial: 8306241
Drug: I.M. clonazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.M. clonazepam (1 to 2 mg)
Trial: 3102056
Drug: melphalan (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: melphalan (8 mg/m2 orally for 4 days)
Trial: 3102056
Drug: melphalan (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: melphalan (6 mg/m2 for 4 days) and hexamethylmelamine (120 mg/m2 for 14 days) every 4 weeks
Trial: 24811085
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (630 nm, 28 mW, continuous wave, 60 s, 1.68 J)
Trial: 21496138
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen 1 g
Trial: 21496138
Drug: PO acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO acetaminophen 1 g
Trial: 25521843
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen
Trial: 27839957
Drug: PO acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO acetaminophen
Trial: 16316746
Drug: Acetyl-L-carnitine (ALCAR)
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-carnitine (ALCAR)
Trial: 16316746
Drug: Acetyl-L-carnitine (ALCAR)
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-carnitine (ALCAR) and Amisulpride
Trial: 10848901
Drug: Intranasal mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal mometasone furoate 200 microgram
Trial: 10848901
Drug: Oral montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral montelukast 10 mg
Trial: 8798046
Drug: Ioxaglate (Hexabrix);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ioxaglate (Hexabrix); 320 mg I/ml, injected at 2 ml/kg b.w. (max 100 ml)
Trial: 920841
Drug: 250 mg/day
RxNorm normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/day of disulfiram
Trial: 920841
Drug: 500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day of disulfiram
Trial: 20401662
Drug: B vitamins
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamins alone (1 mg folic acid, 7.2 mg pyridoxine, 0.02 mg cyanocobalamin daily)
Trial: 20401662
Drug: Antioxidants alone
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidants alone (150 mg ascorbic acid, 67 mg vitamin E, 9 mg β-carotene daily)
Trial: 15979810
Drug: Low-dose alcohol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose alcohol infusion (0.2 g/kg)
Trial: 31374985
Drug: SUCROSE (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUCROSE (50 g sucrose)
Trial: 31374985
Drug: MALT (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MALT (120 mg sucralose matched with 50 g maltodextrin)
Trial: 31374985
Drug: NNS (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNS (120 mg sucralose)
Trial: 29339723
Drug: fasoracetam (NFC-1)
RxNorm normalized name: Fasoracetam
DrugBank: Fasoracetam (DB16163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fasoracetam (NFC-1) 400 mg BID for 4 weeks
Trial: 21802266
Drug: High-mucilage dose
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-mucilage dose (HM)
Trial: 21802266
Drug: Low-mucilage dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-mucilage dose (LM)
Trial: 2236453
Drug: Fluoxetine 60
RxNorm normalized name: fluoxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 60 mg/day
Trial: 1331830
Drug: Granisetron 40
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron 40 micrograms/kg i.v. given once prior to chemotherapy
Trial: 1331830
Drug: Granisetron 160
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron 160 micrograms/kg i.v. given once prior to chemotherapy
Trial: 8383688
Drug: Granisetron (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (both doses)
Trial: 4028771
Drug: Daily dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dressing changes every 24 hours
Trial: 24737912
Drug: Golimumab 50
RxNorm normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab 50 mg
Trial: 25763862
Drug: Golimumab 100
RxNorm normalized name: golimumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab 100 mg
Trial: 26471830
Drug: Golimumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab (both doses)